{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-001098","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.632237+00:00","generated_at":"2026-05-16T00:33:25.095670+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Celldex completes Phase 3 CSU enrollment six months early; cash $518.6M; net loss $1.22/sh Q4","bullets":["Phase 3 CSU program enrolled 1,939 patients across 43 countries; topline data expected Q4 2026, BLA filing planned 2027.","Phase 2 prurigo nodularis and atopic dermatitis studies fully enrolled; data expected summer and late 2026.","Phase 1 CDX-622 (bispecific SCF & TSLP) proof-of-mechanism study in mild-to-moderate asthma initiated.","Q4 2025 net loss $81.3M ($1.22 per share) vs $47.1M ($0.71) year ago; R&D spend rose to $75.3M.","Cash, cash equivalents and marketable securities $518.6M at Dec 31, 2025; runway through 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-001098","json":"https://secwatch.observer/filing/0001171843-26-001098.json","markdown":"https://secwatch.observer/filing/0001171843-26-001098.md","text":"https://secwatch.observer/filing/0001171843-26-001098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000117184326001098/0001171843-26-001098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000117184326001098/f8k_022526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:33:25.095670+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}